Publications by authors named "Yu Noda"

Claim this Profile
P
Point cloud registration algorithm using liver vascular skeleton feature with computed tomography and ultrasonography image fusion.
Satoshi Miura, Masayuki Nakayama, Kexin Xu, Zhang Bo, Ryoko Kuromatsu, Yu Noda

Int J Comput Assist Radiol Surg· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal portal vein thrombosis following combination therapy with atezolizumab plus bevacizumab for hepatocellular carcinoma: an autopsy case report.
Yutaro Mihara, Yu Noda, Kotaro Iemura, Miwa Sakai, Hideki Iwamoto

Clin J Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-time 3D US-CT fusion-based semi-automatic puncture robot system: clinical evaluation.
Masayuki Nakayama, Bo Zhang, Ryoko Kuromatsu, Masahito Nakano, Yu Noda

Int J Comput Assist Radiol Surg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma.
Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Yu Noda

Oncology· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaphorin 6D tunes amygdalar circuits for emotional, metabolic, and inflammatory outputs.
Yoshimitsu Nakanishi, Mayuko Izumi, Hiroaki Matsushita, Yoshihisa Koyama, Diego Diez, Yu Noda

Neuron· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Etsuko Moriyama, Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka, Yu Noda

Curr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma.
Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Yu Noda

Gastro Hep Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Masatoshi Tanaka, Tomotake Shirono, Yu Noda

Int J Mol Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Yu Noda

J Gastroenterol Hepatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, Masatoshi Tanaka, Takashi Niizeki, Yu Noda

Cancer Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Yu Noda

Cancer Commun (Lond)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A case of difficult treatment of infected pseudoaneurysm of the femoral artery during hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Hiroyuki Suzuki, Tomotake Shirono, Takashi Niizeki, Hideki Iwamoto, Shigeo Shimose, Yu Noda

Nihon Shokakibyo Gakkai Zasshi· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei-Gardini, Tsubasa Tsutsumi, Dan Nakano, Yu Noda

Hepatol Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Yu Noda

Hepatol Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Yu Noda

Sci Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Akira Kajiwara, Yu Noda

Hepatol Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Yu Noda

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.
Hiroyuki Suzuki, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Tomotake Shirono, Yu Noda

Front Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Hiroyuki Suzuki, Hideki Iwamoto, Ken Yamamoto, Mai Tsukaguchi, Toru Nakamura, Yu Noda

Gastro Hep Adv· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
Ryoko Kuromatsu, Tatsuya Ide, Shusuke Okamura, Yu Noda, Naoki Kamachi

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
Hiroyuki Suzuki, Takashi Niizeki, Tomotake Shirono, Yusuke Koteda, Yoshinao Kinjyo, Yu Noda

Intern Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma.
Shusuke Okamura, Shigeo Shimose, Takashi Niizeki, Naoki Kamachi, Yu Noda

Mol Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Tomotake Shirono, Yu Noda

Oncology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Yu Noda

Cancer Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis.
Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Yu Noda

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis